Drug Trial Radar · NCT05692908
An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis
Last checked: Nov 19, 2026Latest source record: Apr 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Sep 2023
Primary completion
Sep 2024
Study completion Nov 2024
Sponsor
- Lead sponsor
- Sorrento Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 open-label, dose escalation trial designed to identify the recommended phase 2 dose of STI-6129 by assessing the safety, preliminary efficacy, and immunogenicity in subjects with relapsed or refractory systemic AL Amyloidosis
Conditions
- Light Chain (AL) Amyloidosis
Interventions
STI-6129Biological
Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of STI-6129Time frame: Baseline through study completion at up to approximately 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.